-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Y-mAbs Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2017 to 2023.
- Y-mAbs Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$9.79M, a 35.5% decline year-over-year.
- Y-mAbs Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$27.6M, a 34% increase year-over-year.
- Y-mAbs Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$25.7M, a 72.9% increase from 2022.
- Y-mAbs Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$94.8M, a 17.9% increase from 2021.
- Y-mAbs Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$115M, a 3.75% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)